Form 11-K
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 11-K
ANNUAL REPORT
PURSUANT TO SECTION 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
(Mark One):
     
þ   ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2008
OR
     
o   TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number 000-28782
SPECTRUM PHARMACEUTICALS, INC. 401(K) PLAN
(Full title of the plan)

SPECTRUM PHARMACEUTICALS, INC.
157 Technology Drive
Irvine, California 92618
(Name of issuer of the securities held pursuant to the plan and the address of the issuer’s and plan’s principal executive office)
 
 

 

 


 

TABLE OF CONTENTS
         
    3  
 
       
    3  
 
       
    5  
 
       

 

2


Table of Contents

REQUIRED INFORMATION
Item 1-3. The Spectrum Pharmaceuticals, Inc. 401(k) Plan (the “Plan”) is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). Therefore, in lieu of the requirements of Items 1-3 of Form 11-K, attached are the financial statements of the Plan for the fiscal period ended December 31, 2008, which have been prepared in accordance with the financial reporting requirements of ERISA.
Item 4. Pursuant to Section 103(c) of ERISA, and the regulations thereunder, the Plan is not required to file audited financial statements, because the Plan has fewer than 100 participants.

 

3


Table of Contents

STATEMENT OF INCOME AND EXPENSES
Year Ending December 31, 2008
         
INCOME
       
Contribution — Company Matching (co. stock)
  $ 274,057  
Contribution — Participant 401(k)
    532,134  
Investment Earnings
    72,696  
Cash Value of Surrendered Insurance
    0  
Realized Gain From Asset Sale
    0  
Insurance Premium Refunds
    0  
Other Income — Rollovers
    21,703  
Unrealized Depreciation of Assets
    (648,963 )
 
     
 
       
Total Income
  $ 251,627  
 
     
EXPENSES
       
Life Insurance Premiums Paid
  $ 0  
Payments to Participants
    122,928  
Bank Charges
    0  
Brokerage Fees
    0  
Administration Expenses Paid By the Trust
    0  
Other Miscellaneous Expenses
       
 
     
 
       
Total Expenses
  $ 122,928  
 
     
Income Over Expenses
  $ 128,699  
Assets At The Beginning Of The Plan Year
    1,653,810  
 
     
Assets At The End Of The Plan Year
  $ 1,782,509  
 
     
PLAN ASSETS AND LIABILITIES
                 
    As of     As of  
    January 1,     December 31,  
    2008     2008  
ASSETS
               
Cash (Interest Bearing)
  $ 226,798     $ 493,871  
Contribution Receivable — (Co. Match)
    0       0  
Contribution Receivable — (401-K)
    0       0  
Government Securities
    0       0  
Mutual Funds
    1,141,842       883,904  
Corporate Stocks & Bonds — (Employer Stock)
    218,411       346,980  
Real Estate and Mortgages
    0       0  
Depreciable Buildings/Property
    0       0  
Participant Loans
    66,759       57,754  
Other Assets
    0       0  
 
           
 
               
Total Assets
  $ 1,653,810     $ 1,782,509  
 
           
 
               
LIABILITIES
               
Payables
    0       0  
Acquisition Indebtedness
    0       0  
Other Liabilities
    0       0  
 
           
 
               
Total Liabilities
  $ 0     $ 0  
 
           
 
               
NET ASSETS (Assets Less Liabilities)
  $ 1,653,810     $ 1,782,509  
 
           
SPECTRUM PHARMACEUTICALS, INC. 401(K) PLAN

 

4


Table of Contents

SIGNATURES
The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the Plan) have duly caused this annual report to be signed by the undersigned thereunto duly authorized, in the City of Irvine, State of California, on the 29th day of June 2009.
         
  SPECTRUM PHARMACEUTICALS, INC. 401(K) PLAN
 
  By:   Spectrum Pharmaceuticals, Inc.    
     
  By:   /s/ Shyam Kumaria    
    Shyam Kumaria    
    Vice President, Finance   

 

5